正在加载视频...

视频加载失败

Dr. Benjamin Schrank explains his recent research on a first-in-class antibody-drug conjugate that is designed to trigger an immune response, as a complementary strategy to radiation therapy. Read more: Benjamin Schrank, MD, PhD #ASTRO24 #EndCancer

11,282 次观看 • 1 年前 •via X (Twitter)

4 条评论

Betty Y.S. Kim, MD, PhD, FRCSC, FAIMBE 的头像
Betty Y.S. Kim, MD, PhD, FRCSC, FAIMBE1 年前

@BenjaminSchrank @BenjaminSchrank is without a doubt one of the very best physician scientist trainee I have ever encountered. Quadruple threat: great scientist, leadership skills, gifted educator and super kind/humble. Truly exceptional. He’s also on the job market. So proud!

Benjamin Schrank, MD, PhD 的头像
Benjamin Schrank, MD, PhD1 年前

Thankful to @BettyKimLab and @wenjiang_nano for their continued mentorship and support!

Raffaele Di Giacomo, PhD 的头像
Raffaele Di Giacomo, PhD1 年前

Dr. Schrank's research on the antibody-drug conjugate sounds promising, especially as a complement to radiation therapy. By triggering an immune response, it could enhance the overall effectiveness of cancer treatments – potentially improving patient outcomes. How does this conjugate specifically interact with the immune system compared to other immunotherapies? For those interested in more detailed biomedical insights or reviews, check out – your one-stop platform for every biomedical question. #Medicine #CancerResearch #Immunotherapy

Mother of Swans 的头像
Mother of Swans1 年前

@BenjaminSchrank 👏 LFG! Help me live! #NSCLC #EGFR #OligoBrainMets

相关视频